Skip to main content
UCB logo

UCB — Investor Relations & Filings

Ticker · UCB ISIN · BE0003739530 LEI · 2138008J191VLSGY5A09 BR Manufacturing
Open in API
Filings indexed 2,000 across all filing types
Latest filing 2026-05-03 Regulatory Filings
Country BE Belgium
Listing BR UCB

About UCB

https://www.ucb.com/

UCB is a global biopharmaceutical company that focuses on creating solutions for people living with severe diseases, primarily in the fields of neurology and immunology. The company's core activities include the research, development, and commercialization of pharmaceutical and biotechnology products. Guided by a patient-centric and science-driven approach, UCB is committed to innovation and sustainability. Through its UCB Ventures arm, it invests in pioneering technologies and companies with the potential to transform patient care. The company also offers personalized support services to patients and healthcare professionals during their treatment journey with a UCB medicine.

Recent filings

Filing Released Lang Actions
Candid Therapeutics.pdf
Regulatory Filings
2026-05-03 English
UCB PR Neurona March 17 2026 ENG 1.pdf
M&A Activity Classification · 1% confidence The document is a corporate press release announcing UCB’s definitive agreement to acquire Neurona Therapeutics, detailing transaction terms (upfront payment, milestone payments), strategic rationale, regulatory conditions, and guidance implications. This is a merger and acquisition announcement, not a full annual/interim report or earnings release.
2026-04-17 English
260403 - Acquisition of own shares_ENG Final.pdf
Transaction in Own Shares Classification · 1% confidence The document is a regulated press release disclosing details of UCB’s share repurchase program (quantities, prices, dates), i.e. a transaction in the company’s own shares. This matches the definition for category “Transaction in Own Shares” (POS).
2026-04-03 English
260403- Acquisition actions propres_FR Final.pdf
Transaction in Own Shares Classification · 1% confidence The document is a regulatory announcement by UCB SA detailing its "Programme de rachat d'actions propres 2026," including the number of shares repurchased, dates, prices and totals. This clearly corresponds to a report of the company buying back its own shares. Therefore, it is classified as Transaction in Own Shares (POS).
2026-04-03 French
260403 - Verwerving van eigen aandelen_NL Final.pdf
Transaction in Own Shares Classification · 1% confidence The document is a regulated press release detailing UCB’s share buyback program (“Aandelen Inkoopprogramma 2026”) and the number of its own shares acquired over specific dates, including quantities and prices. This fits the definition of a Transaction in Own Shares (share repurchase) rather than a funding announcement, dividend, or other category.
2026-04-03 Dutch
User Guide Lumi Connect Online Platform - ENG - 2026.pdf
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a pre-meeting information bulletin sent to shareholders explaining how to register for the Annual General Meeting, how to nominate or appoint a proxy, and key dates (record date, closing date). It does not contain the AGM presentation itself (AGM-R) nor full financial statements. Rather, it is part of the proxy solicitation/meeting notice materials providing shareholders with instructions and asking them to register and vote. Hence it best fits the Proxy Solicitation & Information Statement category (PSI).
2026-03-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.